Adolescent dosing and labeling since the food and drug administration amendments act of 2007

JAMA Pediatrics

Volumn 167, Issue 10, 2013, Pages 926-932

  Momper, Jeremiah D ^a   Mulugeta, Yeruk ^a   Green, Dionna J ^a   Karesh, Alyson ^a   Krudys, Kevin M ^a   Sachs, Hari C ^a   Yao, Lynn P ^a   Burckart, Gilbert J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AMOXICILLIN PLUS CLAVULANIC ACID; ATAZANAVIR; AZITHROMYCIN; CASPOFUNGIN; DARUNAVIR; DOCETAXEL; ETIRACETAM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GUANFACINE; LEVOFLOXACIN; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; OLMESARTAN; OMEPRAZOLE; PALIPERIDONE; PANTOPRAZOLE; PARACETAMOL; PEMETREXED; RIZATRIPTAN; ROCURONIUM; ROSUVASTATIN; TENOFOVIR DISOPROXIL; TIPRANAVIR; TOCILIZUMAB; UNINDEXED DRUG; VALGANCICLOVIR; ZOLEDRONIC ACID;

ALLOMETRY; ANTHRAX; ARTICLE; ATTENTION DEFICIT DISORDER; BACTERIAL SINUSITIS; BODY SURFACE; COMMUNITY ACQUIRED PNEUMONIA; CYTOMEGALOVIRUS INFECTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE; DRUG LEGISLATION; FAMILIAL HYPERCHOLESTEROLEMIA; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; JUVENILE RHEUMATOID ARTHRITIS; MIGRAINE; MYCOSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SEIZURE;

ADOLESCENT; ADULT; BODY WEIGHT; DRUG APPROVAL; DRUG LABELING; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84885198399     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2013.465     Document Type: Article

References (29)

1. US Food and Drug Administration. Breakdown of FDAAA completed studies. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ ucm190622.htm. Accessed March 1, 2012.
2. US Food and Drug Administration. FDA Safety and Innovation Act. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ ucm310927.htm. Accessed June 28, 2013.
3. Burckart GJ, Estes KE, Leong R, et al. Methodological issues in the design of pediatric pharmacokinetic studies. Pharm Med. 2012;26:13-22.
4. Code of Federal Regulations. 21CFR56.111. http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=56.111. Accessed September 15, 2012.
5. Meibohm B, Läer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. 2005;7(2):475-487.
6. Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit. 2007;29(3):271-278.
7. Knibbe CA, Zuideveld KP, Aarts LP, Kuks PF, Danhof M. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol. 2005;59(6):705-711.
8. US Food and Drug Administration. Guidance for industry: clinical investigation of medicinal products in the pediatric population. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129477.pdf. Accessed February 1, 2013.
9. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21(4):169-175.
10. McDowell MA, Fryar CD, Ogden CL, Flegal KM. Centers for Disease Control and Prevention. Anthropometric Reference Data for Children and Adults: United States, 2003-2006. Atlanta, GA: National Center for Health Statistics, Centers for Disease Control and Prevention; 2008.
11. US Food and Drug Administration. Medical, statistical, and clinical pharmacology reviews of pediatric studies conducted under section 505A and 505B of the Federal Food, Drug, and Cosmetic Act (the Act), as amended by the FDA Amendments Act of 2007 (FDAAA). http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/ucm049872.htm. Accessed March 1, 2012.
12. Rajagopalan P, GastonguayMR. Population pharmacokinetics of ciprofloxacin in pediatric patients. J Clin Pharmacol. 2003;43(7):698-710.
13. Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm. 1985;13(2):185-201.
14. US Food and Drug Administration. http://www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm. Accessed July 5, 2013.
15. Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol. 2003;43(2):154-162.
16. Yu J, He J, Zhang Y, Qin F, Xiong Z, Li F. An ultraperformance liquid chromatography-tandem mass spectrometrymethod for determination of anastrozole in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2011;25(4):511-516.
17. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43(11):707-724.
18. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry. 2000;61(4):252-260.
19. Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol. 2000;49(suppl 1):57S-60S.
20. Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol. 2010;28(32):4790-4799.
21. Gardner MJ, JuskoWJ. Effect of age and sex on theophylline clearance in young subjects. Pediatr Pharmacol (New York). 1982;2(2):157-169.
22. Lambert GH, Schoeller DA, Kotake AN, Flores C, Hay D. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther. 1986;9(6):375-388.
23. Gardner MJ, Tornatore KM, JuskoWJ, Kanarkowski R. Effects of tobacco smoking and oral contraceptive use on theophylline disposition. Br J Clin Pharmacol. 1983;16(3):271-280.
24. Björkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scalingmethods? Clin Pharmacokinet. 2006;45(1):1-11.
25. Johnson TN. The problems in scaling adult drug doses to children. Arch Dis Child. 2008;93(3): 207-211.
26. Abernethy DR, Burckart GJ. Pediatric dose selection. Clin Pharmacol Ther. 2010;87(3):270-271.
27. Renton KW. Regulation of drugmetabolism and disposition during inflammation and infection. Expert Opin DrugMetab Toxicol. 2005;1(4): 629-640.
28. US Food and Drug Administration. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology Meeting, March 14, 2012. http://www.fda.gov/ AdvisoryCommittees/Calendar/ucm286681.htm. Accessed September 15, 2012.
29. European Medicines Agency. Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003066.pdf. Accessed March 15, 2012.